The SARS-CoV-2 RNA with mild lung lesions lasts longer in non-severe COVID-19 patients: a case series study

Chi Zhang,Jiawen Li,Jing Mu,Daitao Zhang,He Wang,Yunv Jin,Yan Han,Haiyang Li,Chunxiao Zhang,Peng Yu,Rui Guo,Xiangfeng Dou,Yanhui Chu,Zhao Wu,Xiaoqin Dong,Hong Zhao
DOI: https://doi.org/10.21203/rs.3.rs-43643/v1
2020-01-01
Abstract:Abstract Background COVID-19 has become a new infectious disease in the global pandemic, most of which are non-severe patients. It is particularly important to understand the dynamic changes of the whole disease course of non-severe patients from the onset to the follow-up after discharge.Methods On February 1, 2020, 18 cases of non-severe COVID-19 appeared in a hospital in Beijing. We recorded the clinical information and viral dynamics of these patients from the onset of the disease to one month after discharge.Results Eighteen patients (median age 43) were included, including 14 females. Fever (11/18) and cough (8/18) are the most common symptoms. According to the degree of lung inflammation, 18 patients were divided into two groups (group A imaging score ≤ 10; group B imaging score > 10). The duration of SARS-CoV-2 positive in group A was significantly longer than that in group B (the median was 30 and 13, respectively, P = 0.0025). One month after discharge, almost all patients were followed up for IgM antibody disappearance and IgG antibody production.Conclusion In non-severe COVID-19 patients, the positive duration of the SARS-CoV-2 in patients with mild lung injury was longer than that in patients with severe lung injury. The possible mechanism is that the virus-mediated immune system is not fully activated in mild damaged patients.
What problem does this paper attempt to address?